BURLINGTON, N.C., Nov. 7 /PRNewswire-FirstCall/ -- TriPath Imaging, Inc. today announced that the results of an array of clinical and research studies incorporating the SurePath liquid based Pap test as well as the results of research studies incorporating the Company’s ProEx C biomarkers were presented at the 53rd Annual Scientific Meeting of the American Society of Cytopathology in San Diego, California over the past weekend.
Retrospective Review of Long Term Experience at a Community Hospital
In a platform presentation made to the plenary session, Dr. Keith Nance reported a retrospective analysis of a ten year experience at Rex Hospital in Raleigh, North Carolina with conventional and two liquid based methods for cytologic screening for cervical cancer and its precursors. He reported that both liquid based methods provided a higher HSIL rate when compared to the conventional method. In addition, he observed that the SurePath Liquid based Pap test was associated with the highest yield of HSIL detection and the highest specimen adequacy rate of the three Pap test methods.
The analysis presented by Dr. Nance covered a retrospective review of over 300,000 cases processed over a ten year period. This analysis showed that the introduction of the SurePath liquid based Pap test resulted in a statistically significant increase in HSIL detection and a statistically significant reduction in unsatisfactory cases.
SurePath Test Pack Evaluated as Collection Medium for Molecular Testing
Ten of the remaining poster presentations, including one in-house study, reported on testing for molecular markers such as p16, HPV, as well as, mRNA isolation, RT-PCR detection of mRNA, and RT-PCR detection of HPV-E6 mRNA in cells collected using the SurePath test pack. Other studies evaluated the detection of glandular cells, correlation of atypical cytologic classifications with biopsy results, specimen adequacy, alternative collection devices and manual screening times in clinical practice.
“We are delighted by the number of papers that incorporate the SurePath liquid based Pap test,” said Ray Swanson, Senior Vice President of Commercial Operations. “This is a reflection of our success in penetrating the market and expanding clinical adoption of this product.”
TriPath Imaging, Inc., headquartered in Burlington, North Carolina, develops, manufactures, markets and sells innovative solutions to improve the clinical management of cancer, including detection, diagnosis, staging and treatment. TriPath Oncology, a wholly owned subsidiary of TriPath Imaging, develops molecular diagnostic products for malignant melanoma and cancers of the cervix, breast, ovary and prostate. For more information on TriPath Imaging please visit our web site at www.tripathimaging.com.
Investors are cautioned that statements in this press release that are not strictly historical statements constitute forward-looking statements which involve risks and uncertainties that could cause actual results and outcomes to differ materially from what is expressed in those forward-looking statements. Such forward-looking statements include, without limitation, those related to product development efforts. Important factors that may affect such forward-looking statements include, without limitation: TriPath Oncology may be unable to successfully develop and commercialize products and services when anticipated, if at all; TriPath Imaging’s products may not achieve or maintain market acceptance to the degree anticipated; TriPath Imaging and TriPath Oncology’s products may not receive FDA or other required regulatory approval when expected, if at all; and other risks detailed in TriPath Imaging’s filings with the Securities and Exchange Commission, including those described in TriPath Imaging’s Annual Report on Form 10-K for the year ended December 31, 2004.
TriPath Imaging, Inc.
CONTACT: Stephen P. Hall, Chief Financial Officer of TriPath Imaging,+1-336-290-8721
Web site: http://www.tripathimaging.com//
